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Background: A number of clinicopathological characteristics can inﬂuence survival following esoph-
agectomy for cancer. The aim of this study was to determine the factors affecting survival in a consec-
utive series of patients undergoing esophagectomy for cancer at a single tertiary centre over a 7 year
period.
Materials & methods: We analyzed a prospective database of 314 consecutive patients (247 males and 67
females), with a mean age of 62.8 þ/ 9.1 years, who underwent esophagectomy for cancer at a single,
high-volume centre between January 2000 and June 2007. The impact of 11 variables on survival
following esophagectomy was determined by univariate and multivariate analysis.
Results: On univariate analysis, gender, ASA grade, blood transfusion, type of cancer, tumor stage, lymph
node status, lymphovascular invasion (LVI), longitudinal resection margin (LRM) involvement and
circumferential resection margin (CRM) involvement were signiﬁcant (p< 0.05) negative factors for
survival. Multivariate analysis using Cox proportional hazard regression demonstrated that the only
independent factors negatively impacting on survival were ASA grade (p¼ 0.012), tumor stage
(p¼ 0.009), LVI (p¼ 0.009) and LRM involvement (p¼ 0.031).
Conclusions: In the current study we demonstrated that independent variables effecting survival after
esophagectomy for cancer were ASA grade, tumor stage, lymphovascular invasion and longitudinal
resection margin involvement. Contrary to other studies we did not ﬁnd CRM involvement to be an
independent predictor for survival.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Over the past 30 years, the incidence of esophageal carcinoma
has increased markedly.1 Adenocarcinoma (ADC) has steadily
surpassed squamous cell carcinoma (SCC) and now accounts for
70% of esophageal cancer in the United Kingdom, where it is the
ﬁfth leading cause of cancer related mortality.2 Carcinomas of the
esophagus behave in an aggressive manner and are capable of early
dissemination by both lymphatic and haematogenous means;
radical surgery (with or without adjuvant chemoradiotherapy)
remains the curative option of choice. Once regarded as futile,
advances in pre-operative staging, reﬁnement of operative tech-
nique and improved postoperative critical care mean that esoph-
agectomy can now be performed with acceptable morbidity and
mortality at experienced centers.ax: þ44 020 7340 5111.
irnezami).
ciates Ltd. Published by Elsevier LtIn spite of this, the prognosis for advanced disease remains
poor;3 many patients present with disease recurrence within 2
years of curative resection4 and reported 5-year survival ranges
from 20 to 40% in the literature.4–6 Accurate staging is essential in
determining prognosis and appropriately selecting patients for
adjuvant therapy. Staging at present is based largely on the TNM
classiﬁcation system proposed by the American Joint Committee in
Cancer (AJCC) in 1988 and subsequently revised to its current form
in 2002. However, mounting controversy exists regarding the
current system for esophageal cancer staging. A number of authors
have suggested that the current system combines patients with
very different outcomes into each disease stage, and uncertainty
remains regarding its application to patients who may have
undergone tumor regression following neo-adjuvent chemo-
therapy prior to surgery.7 Recent proposed revisions to the present
staging system include subdivision of the T1 stage to T1a and T1b
tumors8 (intramucosal and submucosal respectively), and revised
nodal status categorization.9 The notion that further reﬁnement isd. All rights reserved.
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of various pathological factors on survival after esophagectomy.
Through such studies patient factors, such as ASA grade,10 tumor
related factors such as tumor type,7,11 tumor stage,12 and inva-
siveness,13 and perioperative factors, such as need for blood
transfusion14,15 have been identiﬁed as possible variables inﬂu-
encing outcome. The speciﬁc role of each of these factors remains
uncertain, and the available evidence is often conﬂicting. Our study
evaluates the impact of various clinicopathological factors on
survival following esophageal resection in a large cohort of patients
over a 7 year period.
2. Patients and methods
2.1. Study population
Between January 2000 and June 2007, 383 patients with a pre-
operative diagnosis of esophageal carcinoma underwent esoph-
agectomy with curative intent at a tertiary centre (St Thomas’
Hospital, London). Pre-operatively all patients underwent staging
with endoscopic evaluation and computed tomography (CT). From
2007 onwards all patients underwent routine pre-operative
endoscopic ultrasound (EUS) and CT-PET scans. All cases were
discussed at an upper GI multi-disciplinary meeting (MDM) pre-
and postoperatively. Patients presenting in the last 2 years under-
went additional cardiopulmonary exercise testing prior to
resection.
All operations were performed, or closely supervised by two
consultant esophago–gastric surgeons (R.C.M and A.B). Patients
underwent transhiatal, Ivor-Lewis, 3-stage or thoraco–abdominal
oseophagectomy depending on tumor location and surgeon
preference. In all cases complete macroscopic tumor clearance was
sought, though extended lymphadenectomy was not routinely
performed.
Postoperatively patients were ventilated overnight in our
recovery room and then transferred to the ward or high depen-
dency unit depending on their clinical condition or co-morbidities.
Pathology specimens were all assessed by a team of three specialist
upper gastro–intestinal histopathologists. Follow up was initially at
6 weeks from discharge and then subsequently 3-monthly for
a year, 6-monthly for another 2 years, and then yearly.
2.2. Data extraction
Since January 2000, outcome data for all patients undergoing
esophageal resection at our hospital has been collected in
a prospective database. For each patient, data on the following
variables was retrospectively extracted from this database: gender,
age, ASA grade, need for peri-operative blood transfusion, timing
of blood transfusion, type of cancer, stage of cancer, lymph node
status, lymphovascular invasion (LVI), longitudinal resection
margin (LRM) involvement, circumferential resection margin
(CRM) involvement, development of local recurrence or distant
metastases, last follow up and cause of death. To obtain as
homogenous a patient cohort as possible, patients with no
evidence of malignancy on ﬁnal histopathological evaluation, or
with lesions other than SCC and ADC were excluded from the
analysis, leaving a total of 314 patients in the present study
(Fig. 1).
2.3. Statistical analysis
Follow up was until June 2007 or until death if earlier. Overall
survival was calculated using the Kaplan–Meier method and
included perioperative deaths. Independent variables were ﬁrstanalysed with univariate analysis. Variables shown by univariate
analysis to be signiﬁcantly associated with survival were entered
into a Cox proportional hazards regression model for multivariate
analysis. Statistical signiﬁcance was deﬁned as p< 0.05. All statis-
tical analyses were performed using SPSS version 12 (SPSS, Chicago,
IL, USA).
3. Results
3.1. Patient characteristics
Of the 314 patients undergoing oesophagectomy, 247 weremale
(79%) and 67 were female (21%). Age ranged from 31 to 88 years,
with a mean age of 62.8 þ/ 9.1 years. Patients aged 63 years
made up 50% whilst those aged 64 years constituted the
remainder. Two-hundred and sixteen patients (69%) were
pre-operatively classed as ASA Grade 1 or 2, and 98 patients (31%)
were ASA Grades 3 and 4. Peri-operative blood transfusion was
administered to 145 patients (46%). Regarding choice of operation,
transhiatal oesophagectomy was performed in 193 patients (61%).
Seventy-nine patients underwent Ivor-Lewis oesophagectomy
(25%); a 3-stage oesophagectomy was performed in 8 patients (3%),
and thoraco–abdominal oesophagectomy was performed in the
remaining 34 patients (11%).
3.2. Survival and prognostic factors
Overall cumulative survival rates were 79% at 1 year, 56% at 3
years and 46% at 5 years. Univariate analysis found prognosis to be
signiﬁcantly related to 9 of the 11 clinicopathological factors
investigated (Table 1). These variables were: gender, ASA grade,
peri-operative blood transfusion, type of cancer, stage of cancer,
lymph node status, LVI, LRM involvement, and CRM involvement.
Multivariate analysis of the 9 signiﬁcant variables determined
by univariate analysis identiﬁed four prognostic factors that
independently impacted on survival in our cohort of patients (Table
1). These were ASA grade, stage of cancer, LVI and LRM involve-
ment. The mean survival for patients with ASA grades 1 or 2 was
52.05 þ/ 3 months, compared with 35.20 þ/ 3.5 months
(p¼ 0.012). A statistically signiﬁcant survival beneﬁt was also seen
in those patients with lower cancer stage (57.76 þ/ 3 months for
Stage 1 and 2 vs. 28.50 þ/ 3 months for Stage 3 and 4; p¼ 0.009).
Patients with evidence of LVI on histopathological assessment had
a mean survival of 34.47þ/months compared with 58.08þ/ 3.3
months in those with no evidence of LVI (p¼ 0.009). In addition
the multivariate analysis revealed that positive LRM impacted
negatively on overall survival compared with negative LRM (13.17
þ/ 3.6 months vs. 48.24 þ/2.5 months respectively; p¼ 0.031).
Figs. 2–5 show the Kaplan–Meier survival curves for patients after
oesophagectomy in relation to these independent prognostic
variables.
4. Discussion
In recent years we have witnessed a sharp decline in post-
operative morbidity and mortality following esophagectomy.
A retrospective analysis of 32,000 patients undergoing esoph-
agectomy published in 1980 reported a 29% collective operative
mortality from the included studies.16 By comparison, in 2007
Orringer et al. reported an overall hospital mortality of just 3%
following esophagectomy in a large series of over 2000 patients.17
This dramatic improvement is likely attributable to a number of
factors including technical reﬁnement, surgical sub-specialization,
improved pre-operative diagnosis and staging, and improved
critical care. In parallel, we have witnessed an improvement in
Patients excluded with other tumour types on specimen (n=9) - 
leiomyoma (4); spindle cell tumour (1); myxoid leiomyosarcoma (1); 
GIST (3) 
Patients excluded with HGD only on specimen (n=17) 
Patients excluded for no evidence of malignancy on specimen (n=26) 
Patients identified from database (n=383) 
Patients included in the present study n=314 
Patients excluded owing to incomplete data set (n=17) 
Fig. 1. Patients undergoing esophagectomy between January 2000 and June 2007. Patients excluded from the present study are shown.
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was reported as ranging from 3 to 5%,16 current 5-year survival after
esophagectomy ranges from 20 to 40% in the literature.4–6
However, advanced disease stage is still associated with a very
poor prognosis. At present prognostic estimates are principally
based on the pTNM classiﬁcation system, the accuracy of which has
been repeatedly questioned over the last decade.8,18 The pTNM
system is essentially based on 3 pathological aspects: the depth of
mural invasion (T category), the presence or absence of involved
lymph nodes (N category) and distant metastasis (M category);
previous studies have suggested that a number of additional factors
can inﬂuence prognosis following esophagectomy, including lymph
node status,19 lymphovascular invasion,20 and CRM involvement.21
The current pTNM system does not adequately take all of these into
account. Investigation into the clinicopathological factors that
inﬂuence outcome is valuable as it provides further clues as towhat
factors can estimate outcome. It was with this aim that we
conducted the present study.Table 1
Univariate and Multivariate analysis of clinicopathological factors inﬂuencing survival.
Characteristics Variation N % Mean Survival
(months þ/ s d
Gender Female 67 21 57.0 (5.0)
Male 247 79 41.6 (2.5)
Age  63 158 50 46.3 (3.3)
 64 156 50 45.3 (3.2)
ASA 1 & 2 216 69 52.1 (3.0)
3 & 4 98 31 35.2 (3.5)
Blood Transfusion No 169 54 51.3 (3.1)
Yes 145 46 39.3 (3.3)
Time of Blood Transfusion  72 hours 96 66 39.8 (4.1)
> 72 hours 49 34 34.8 (4.7)
Type of cancer SCC 51 16 56.4 (5.3)
ADC 263 84 44.4 (2.6)
Stage of Cancer I & II 192 61 57.8 (3.0)
III & IV 122 39 28.5 (3.0)
Lymph node status N0 126 40 61.1 (3.5)
N1 188 60 34.1 (2.8)
LVI No 140 45 58.1 (3.3)
Yes 174 55 34.5 (3.0)
LMR status Negative 293 93 48.2 (2.5)
Positive 21 7 13.2 (3.6)
CRM Status Negative 168 54 48 2 (3.0)
Positive 146 46 41.6 (3.4)4.1. Patient and clinical factors
A number of factors had a signiﬁcant effect on univariate anal-
ysis. Contrary to ﬁndings of other authors22,23 we found that male
gender impacted negatively on overall survival on univariate, but
not multivariate analysis. Morito et al. found male gender to be
a signiﬁcant negative prognostic variable on both univariate and
multivariate analysis in a series of 1000 consecutive patients
undergoing esophagectomy for cancer.24 Hajian-Tilaki has sug-
gested that this associationmay be related to hormonal factors such
as testosterone and androgens.25 In the present study, on multi-
variate analysis the association between gender and survival was
not found to be signiﬁcant. Women accounted for only 21% of our
patient cohort and thus limited power secondary to lownumbers in
this group may explain our contradictory ﬁndings.
We found no signiﬁcant difference in survival when looking at
age, and do not feel that age alone represents a prognostic factor to
predict outcome, a view shared by other authors.26,27 The overall)
Univariate Analysis Multivariate Analysis
HR 95% CI p HR 95% CI p
1 1
1.29 1.03–1.62 0.028 1.3 0.91–1.70 0.059
1
1.02 0.86–1.21 0.812
1 1
1.81 1.28–2.56 0.001 1.57 1.10–2.24 0.012
1 1
1.27 1.07–1.51 0.006 1.19 0.99–1.41 0.057
1
1.04 0.64–1.69 0.876
1 1
1.69 1.08–2.63 0.020 1.16 0.84–1.59 0.363
1 1
3.25 2.23–4.76 <0.001 1.39 1.09–1.77 0.009
1 1
2.46 1.74–3.50 <0.001 1.18 0.91–1.50 0.299
1 1
2.35 1.65–3.36 <0.001 1.31 1.07–1.6 0.009
1 1
1.93 1.41–2.65 <0.001 1.43 1.04–1.98 0.031
1 1
1.25 1.05–1.48 0.011 1.1 0.86–1.30 0.58
Fig. 2. Kaplan–Meier Survival Function – ASA Grade.
Fig. 4. Kaplan–Meier Survival Function –Lymphovascular Invasion (LVI).
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not represent an impediment to esophageal resection in a patient
otherwise deemed ﬁt for surgery.
A number of studies have demonstrated that cardiopulmonary
complications account for a signiﬁcant proportion of postoperative
deaths following esophagectomy,28–30 and predictably our study
found patients with ASA Grades 3 and 4 had signiﬁcantly lower
overall survival compared with ASA Grades 1 and 2. This was
statistically signiﬁcant on both univariate and multivariate analysis
in our patient cohort. At our hospital patients in ASA Grades 3 and 4
routinely undergo detailed cardiological review including echo-
cardiography and pulmonary function assessment to evaluate
ﬁtness for resection.
A number of previous studies have looked at the effect of peri-
operative blood transfusion on disease recurrence and overall
survival following esophagectomy for cancer. It has been postulated
that blood transfusion can induce clinically signiﬁcant transfusion-
associated immunosupression, which may increase the rate of
tumor recurrence. The ﬁndings in the literature are somewhat
conﬂicting. Multivariate analysis by Dresner et al. found bloodFig. 3. Kaplan–Meier Survival Function – Stage of Cancer.transfusion in excess of 4 units to be independently associated with
decreased overall survival following esophagectomy for cancer.15
In contrast Nozoe et al. found peri-operative blood transfusion to be
associated with unfavourable survival on univariate analysis but it
was not found to be independently signiﬁcant on multivariate
analysis. The authors concluded that patients with more advanced
tumors required more transfusion due to more difﬁcult dissection
and that this accounted for why they faired worse.31 In agreement
with Nozoe et al.31 we found peri-operative blood transfusion to be
a signiﬁcant predictor of survival on univariate but not multivariate
analysis. We cannot support the hypothesis that increased stage
increased need for blood transfusion as this ﬁnding was not
observed in our study. However, for over a decade we have been
using packed red cells for blood transfusion as apposed to whole
blood. As this is deplete of white blood cells, which are primarily
thought to be responsible for exerting the immunomodulatory
effect, this may explain why we did not ﬁnd a signiﬁcant decreased
survival in our study.Fig. 5. Kaplan–Meier Survival Function – Longitudinal Resection Margin (LRM)
Involvement.
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experienced in all 4 operation types performed in our patient
cohort and have their preferred approaches, depending on patient
and tumor factors. The prognostic signiﬁcance of type of operation
was not evaluated in the present study and though this may be
considered a limitation, large studies have previously demon-
strated no signiﬁcant difference in long-term survival or disease
recurrence when comparing transabdominal with transthoracic
oesophagectomy.32,33 The authors recognize that the approaches
will undoubtedly yield differing numbers of lymph nodes.
However, though it has been suggested that transthoracic dissec-
tion provides improved surgical exposure for harvesting medias-
tinal lymph nodes, the long term oncological beneﬁts of this remain
uncertain.
4.2. Pathological factors
Published data regarding the association between histopatho-
logical tumor type and prognosis is conﬂicting. In support of
ﬁndings by a number of other authors7,11 we observed that on
univariate analysis, adenocarcinoma had reduced overall survival
time compared with squamous cell carcinoma, though this did not
reach statistical signiﬁcance on multivariate analysis. The exact
reason for this remains uncertain; Khan et al. suggested that earlier
presentation of mid-oesophageal tumors (usually squamous cell
carcinoma) conferred an advantage compared with lower tumors
(typically adenocarcinomas) which are usually more advanced at
presentation.11 In contrast Stein et al. found superior survival in
patients with early adenocarcinoma compared with squamous cell
carcinoma.34 They hypothesized that one reason for this observa-
tion could be that patients with squamous cell carcinoma usually
have more severe comorbid conditions, a worse nutritional and
functional status and lower socioeconomic status.35
Predictably we found pTNM stage to be strongly associated with
survival both on univariate and multivariate analysis. Patients with
stage 3 and 4 disease, in accordancewith the UICC criteria set out in
2002,36 faired unfavourably compared those with stage 1 and 2
disease. This serves to again highlight the poor prognosis associated
with advanced disease, and underlines the importance of timely
and accurate pre-operative diagnosis and staging.
The exact pattern of lymphatic involvement, the indications for
lymphadenectomy and the extent of lymph node dissection remain
controversial in the scope of esophageal cancer. In the present
study node-negative patients had an overall survival of 61 months
and patients with node-positive disease had an overall survival of
34months. This differencewas found to be signiﬁcant on univariate
but not onmultivariate analysis. At our centre removal of the cancer
in its entirety together with the surrounding tissues and adjacent
lymph nodes is the standard practice. However it is not our routine
practice to perform extended lymphadenectomy, as we do not feel
this confers a survival advantage. We feel our results support this
practice though we appreciate that our approach to lymphade-
nectomy is not universally shared. A limitation of the present study
may be that the N1 stage has not been further subdivided nor have
we expressed the lymph node status in terms of lymph node ratio
(LNR) as put forward by Rice et al.8 This may account for the loss of
statistical signiﬁcance on multivariate analysis.
A factor determined by multivariate analysis as an independent
predictor of survival was the presence of lymphovascular invasion
(LVI). Other studies have found a similar association, and our
ﬁndings further underline the importance of this factor in long
term survival. Lymphatic vessel invasion is thought to precede or
occur in synchrony with lymph node metastasis. The close
relationship is evidenced by observations by a number of authors
of correlation between LVI and lymph node status. Brucher andcolleagues found that 75.8% of patients with LVI had lymph node
metastasis in a study of 366 patients.37 In addition the authors
found that LVI was present in 21% of patients with UICC stage 1
disease.37 This demonstrates that seemingly local tumors may
already possess features of systemic and not just local spread. Our
ﬁndings here support those of other authors and we feel that this is
a strong case for inclusion of LVI in the UICC staging system as
a robust independent marker of prognosis.
The association between longitudinal resection margin (LRM)
involvement and adverse survival outcome is widely agreed. The
incidence of microscopically positive (R1) longitudinal resection
margins (LRM) in the present series was 7%, which compares
favorably with reports in the literature. Involvement of LRM was
shown to be signiﬁcant on both univariate andmultivariate analysis
and is a robust predictor of survival.
In the present studywe found that the association between CRM
involvement and unfavourable survival did not reach statistical
signiﬁcance on multivariate analysis, and thus conclude that CRM
involvement is not an independent factor inﬂuencing survival in
resected oesophageal cancer. Reports in the literature on this topic
are conﬂicting. Interest in CRM involvement in esophageal cancer
stems largely from compelling observations in rectal cancer, where
it has been shown to be a predictor of local recurrence38 and of long
term survival.39 Several authors have demonstrated a similar
association in esophageal cancer.21,40 However, this ﬁnding has not
been universally demonstrable. Our ﬁnding that CRM involvement
is not a signiﬁcant independent predictor of survival is supported
by observations made by Thompson et al.7 and Khan et al.19 The
exact reason for these differing results remains uncertain at
present. Thompson et al. emphasize that in their study, 68% of
patients with CRM involvement were node positive, and conversely
65% of patients without CRM involvement were node negative –
they concluded that in their study, the survival advantage conferred
by a negative CRM was due to absence of metastatic lymph nodes.7
Future studies will likely clarify this issue further.5. Conclusion
An accurate guideline based staging system that is universally
accepted by surgeons, radiologists and oncologists is critical in
allowing early diagnosis of esophageal cancer and in providing
evidence on both prognosis, and suitability for adjuvant therapy.
The reliability of the current model has been questioned repeatedly
in the last few years, though fewwidely agreed revisions have been
agreed. This is in part owing to widely conﬂicting reports in the
literature, with heterogenous study populations and varying
patient numbers. The present study evaluated survival in a large
cohort of patients and found that independent pathological factors
inﬂuencing survival following esophagectomy were tumor stage,
lymphvascular invasion, and positive longitudinal resection
margins. Our data support the inclusion of LVI in the UICC classi-
ﬁcation system for esophageal cancer, and supports the notion that
further reﬁnement of the current UICC model may allow more
accurate patient stratiﬁcation.Contributions
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